The ANR launches in collaboration with the ERA-NET JPcofuND 2 a joint call to support multinational, collaborative research projects addressing the Personalised Medicine for Neurodegenerative Diseases. More than €30 million have already been earmarked by JPND member countries and the European Commission for this action.
The present call is supported by 24 member countries: Australia, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Turkey and United Kingdom.
The aim of the call is to finance ambitious, innovative, multinational and multidisciplinary projects that address precision medicine approaches for the neurodegenerative diseases.
Neurodegenerative diseases are debilitating and still largely untreatable conditions. They are characterised by a large variability in their origins, mechanisms and clinical expression. When searching for a medical solution, e.g. a treatment or an optimised approach for care, this large variability constitutes a major hurdle if not controlled. Indeed a treatment addressing one disease pathway may not be useful for all patients experiencing the relevant symptoms. Thus, one of the greatest challenges for treating neurodegenerative diseases is the deciphering of this variability.
JPND has chosen to focus in the area of Precision Medicine, which relates to the targeting of specific elements responsible for pathology in a given individual at a particular point in time. It is an emerging approach for disease prevention, diagnosis and treatment that takes into account individual variability in genes, biological/molecular characteristics together with environmental and lifestyle factors.
Thus, the upcoming call for multidisciplinary research proposals conducted by JPND and the European Commission will focus on Precision Medicine in the following research areas:
The following neurodegenerative diseases are included in the call:
Proposals should have novel, ambitious aims and ideas combined with well-structured work plans and clearly defined objectives deliverable within three years. Where proposals are complementary to work funded or applied for under other initiatives, this should be indicated, so that it is clear how any work supported by JPND will add value. Each consortium should have the critical mass to achieve the identified scientific goals and the proposals should specify the added value of working together. Applicants should demonstrate that they have the expertise and range of skills required to conduct the research project or that appropriate collaborations are in place. The value that will be added to ongoing national activities and the expected impact on future medical as well as health and social care for people suffering from neurodegenerative diseases should be explicitly stated.
Ethically appropriate access to and synergistic usage of resources, e.g. data from patients and health care providers or existing population and disease-specific cohorts and registries, is expected. To increase added value, data, tools and resources being generated within the research projects should be made widely available in the public domain, taking into account national and international legal and ethical requirements. Access must be provided to other bona fide research groups. Consortia are strongly advised to define arrangements to deal with this issue across countries, while preserving integrity of study subjects.
Proposals should address socio-economic factors, gender-related research questions and comorbidities, where appropriate. Consortia should incorporate these factors when formulating their research hypotheses, aims and work plans. Cross-cultural issues and diversity, should be taken into account, particularly when developing and implementing instruments and intervention strategies.
Selected projects can be funded for a duration up to three years. Funding is expected to start end 2019.
It is strongly recommended that all applicants thoroughly read the information provided above.
Contact Persons for the Joint Call Secretariat
Dr. Sheyla Mejia-Gervacio
+ 33 1 78 09 80 14